Motexafin gadolinium: a possible new radiosensitiser

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.12, Iss.7, 2003-07, pp. : 1205-1210

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Motexafin gadolinium: a promising radiation sensitizer in brain metastasis

By Thomas Sayana Rachel Khuntia Deepak

Expert Opinion on Drug Discovery, Vol. 6, Iss. 2, 2011-02 ,pp. : 195-203

Informa Healthcare

Access to resources Recommend Favorite

Motexafin Gadolinium: Gadolinium (III) Texaphyrin, Gadolinium Texaphyrin, Gd-Tex, GdT2B2, PCI 0120

By Adis International Limited

Drugs in R&D, Vol. 5, Iss. 1, 2004-01 ,pp. : 52-57

Adis International

Access to resources Recommend Favorite

Population pharmacokinetics and bioavailability of motexafin gadolinium (Xcytrin^®) in CD1 mice following intravenous and intraperitoneal injection

By GW Boswell Miles DR Thiemann PA Mesfin M

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 281-289

Springer Publishing Company

Access to resources Recommend Favorite

Gadolinium-containing contrast agents: new safety data

Reactions Weekly, Vol. 1, Iss. 1144, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

New warnings for gadolinium-containing contrast agents

Reactions Weekly, Vol. 1, Iss. 1319, 2010-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite